Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Palbociclib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 20 Oct 2017 Status changed from recruiting to discontinued because the data from the first 12 participants made it apparent that the study was not going to meet the primary endpoint
- 10 Mar 2017 Planned End Date changed from 1 Jan 2025 to 1 Jul 2021.
- 10 Mar 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jul 2017.